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KAJIAN KEIMUNAN Mycobacterium smegmatis REKOMBINAN YANG 
MENGEKSPRES ANTIGEN 85B SEBAGAI CALON VAKSIN BERPOTENSI 
TERHADAP TUBERCULOSIS 
 
ABSTRAK 
 
Penyakit Tuberculosis (TB) masih kekal sebagai penyumbang kepada masalah 
kesihatan sedunia yang mengakibatkan lebih daripada 1.3 juta kematian setiap tahun. 
Pembangunan vaksin yang baharu sebagai pengganti kepada vaksin Bacille Calmette 
Guerin (BCG) atau bertujuan meningkatkan keberkesanannya adalah merupakan 
matlamat utama yang telah disarankan oleh Pertubuhan Kesihatan Sedunia (WHO). 
Mycobacterium smegmatis (M. smegmatis) adalah sejenis mikroorganisma yang 
tidak patogenik dan merupakan komensal kepada manusia, dan ia mempunyai ciri-
ciri yang hampir sepadan dengan Mycobacterium tuberculosis (M. tuberculosis). 
Vektor mikobakteria hidup termasuk M. smegmatis telah berjaya digunakan sebagai 
vaksin eksperimentasi terhadap TB. Dalam kajian ini, Mycobacterium smegmatis 
rekombinan yang mengekspresi epitope Ag85B terpilih (P1, P2 dan P3) telah 
dihasilkan (rMs064). Kesan immunomodulasi oleh rMs064 terhadap sel makrofaj 
mencit J774A.1 telah dinilai dalam kajian ini. Keputusan dari eksperimen mendapati 
keupayaan rMs064 untuk merangsang pengekspresian penanda pengaktifan 
makrofaj; MHC kelas II dan molekul CD40 dan merangsang penghasilan sitokin IL-
6, IL-10 dan IL-12p70. Kedua-dua strain rMs064 dan M. smegmatis yang di 
transformasikan dengan plasmid kosong (rMs012 sebagai kawalan) juga berupaya 
mempengaruhi aktiviti fagosit dan mengaktifkan fungsi bakterisid oleh sel makrofaj, 
merembeskan penghasilan enzim “inducible nitric oxide synthase” (iNOS) dan 
penghasilan nitrik oksida (NO). Tindakbalas yang dinyatakan  merupakan bahan 
 xvi 
 
perantara yang penting untuk aktiviti anti-mikobakteria oleh sel makrofaj mencit. 
Kami juga menentukan aktiviti autofagi dengan kuantifikasi protein LC3B-II pada 
sel makrofaj yang telah dijangkiti rMs064. Walaubagaimanapun, keputusan 
mendapati aktiviti autofagi dalam sel makrofaj yang telah di jangkiti oleh rMs064 
adalah tidak konklusif dalam kondisi eksperimen kami. Seterusnya, rMs064, rMs012 
dan PBS (kawalan) telah diimunisasi kepada mencit Balb/C untuk kajian keimunan. 
Penentuan keupayaan rMs064 untuk mengaruh penghasilan tindakbalas sel dan 
humoral terhadap epitop spesifik yang diekspres telah dijalankan. Kami mendapati 
proliferasi signifikan sel limpa yang diasingkan dari mencit yang telah diimuninasi 
dengan rMs064 memberikan tindakbalas yang spesifik  terhadap epitope P2 dan P3, 
berbanding kawalan. Penghasilan sitokin dan immunoglobulin G (IgG) total serta 
subkelas  IgG juga ditentukan terhadap mencit yang telah diimunisasi dalam kajian 
ini. Penghasilan sitokin IFN-γ adalah signifikan hanya pada sel limpa dari kumpulan 
mencit yang diimunisasi dengan rMs064 yang di aruh oleh epitop P1, apabila 
dibandingkan dengan kedua-dua kumpulan mencit kawalan. Untuk penentuan tahap 
pengaktifan sel T oleh rMs064, mencit telah diimunisasi dengan rMs064, rMs012, 
PBS dan KLH-85B. Sel makrofaj yang telah dijangkiti rMs064 dan di ko-kultur 
dengan sel limpa yang telah disensitasikan dengan KLH-85B didapati merangsang 
penghasilan sitokin IFN-γ dan TNF-α yang signifikan. Penghasilan IgG total dan 
subkelas IgG1 menunjukkan peningkatan yang signifikan dalam serum kumpulan 
mencit yang diimunisasi dengan rMs064 yang diaruh oleh epitop P1, P2 dan P3, 
berbanding kumpulan mencit kawalan. Walaubagaimanapun, serum daripada 
kumpulan mencit yang diimunisasi dengan rMs064 berupaya meningkatkan 
penghasilan subkelas IgG2a dan IgG2b yang signifikan apabila diaruh oleh epitop 
P2. Keputusan kajian keimunan menunjukkan mencit yang di imunisasi dengan 
 xvii 
 
rMs064 berupaya menghasilkan tindak balas cenderung kepada jenis keimunan Th1. 
Sebagai kesimpulan, keputusan eksperimen modulasi keimunan secara in vitro di 
dalam sel makrofaj mencit J774A.1 dan kajian tindakbalas keimunan pada mencit 
yang diimunisasi dengan rMs064 menunjukkan potensinya sebagai calon vaksin TB 
untuk eksperimen cabaran pada masa hadapan.  
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IMMUNOGENICITY OF RECOMBINANT Mycobacterium smegmatis 
EXPRESSING   ANTIGEN 85B EPITOPES AS A POTENTIAL 
TUBERCULOSIS VACCINE CANDIDATE 
ABSTRACT 
 
Tuberculosis (TB) remains a major worldwide health problem which causes more 
than 1.3 million deaths annually. The development of a new vaccine as a replacement 
of Bacille Calmette Guerin (BCG) or to improve its efficacy is one of the goals 
mooted by the World Health Organization (WHO) to control TB. Mycobacterium 
smegmatis (M. smegmatis) is nonpathogenic and commensal in humans, which 
shares many characteristics with Mycobacterium tuberculosis (M. tuberculosis). 
Mycobacterial vectors including M. smegmatis have been successfully used in the 
development of experimental vaccines against TB. In the current study, recombinant 
M. smegmatis expressing selected Ag85B epitopes (P1, P2 and P3) was constructed 
(rMs064). The immunomodulatory effects of rMs064 were evaluated in J774A.1 
murine macrophage cells. Our results demonstrated the capacity of rMs064 to induce 
the expression of the macrophage activation markers; MHC class II and CD40 
molecules, and the production of IL-6, IL-10 and IL-12p70 cytokines. Both rMs064 
and M. smegmatis transformed with the empty plasmid (rMs012 as a control) were 
capable to induce phagocytic and mycobactericidal activity in macrophages as well 
as the production of IL-1β and TNF-α cytokines. In addition, J774A.1 macrophages 
infected with both rMs064 and rMs012 also increased the expression of inducible 
nitric oxide synthase (iNOS) and the production of nitric oxide (NO), which are 
crucial mediators of anti-mycobacterial activity. The induction of autophagy as 
quantified by LC3B-II detection in rMs064 infected macrophages showed 
inconclusive results in our experimental conditions. The capacity of rMs064 to 
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induce specific cellular and humoral immune responses in Balb/C mice against the 
expressed epitopes was evaluated. The proliferative responses of splenocytes from 
rMs064-immunized mice stimulated with P2 and P3 epitopes showed significant 
increase as compared to control groups. Cytokine production by splenocytes upon 
stimulation with Ag85B epitopes and serum specific IgG and its subclasses were 
determined. The results showed significant production of IL-12p70 and IL-23 when 
splenocytes were stimulated with P1, P2 and P3 epitopes in mice immunized with 
rMs064. In addition, significant IFN-γ production was found in splenocytes of 
rMs064-immunized mice when stimulated only with P1 epitope. For the evaluation 
of the T cell activation by rMs064, mice were immunized with rMs064, rMs012, 
PBS and KLH-85B. Macrophages infected with rMs064 and co-cultured with KLH-
85B sensitized splenocytes induced significant production of IFN-γ and TNF-α. The 
specific total IgG and IgG1 subclass showed significant increase against all three 
Ag85B epitopes on rMs064-immunized mice as compared to controls. rMs064 
immunized mice showed significant increase of IgG2a and IgG2b only against P2 
epitope. Results of cellular and humoral immunogenicity showed the induction of 
potent Th1 type immune responses in rMs064 immunized mice. Taken together, the 
results of in vitro immunomodulatory effects and immunogenicity support the future 
evaluation of rMs064 as an experimental vaccine against TB in challenge 
experiments.  
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 CHAPTER 1
INTRODUCTION 
 
 General history of tuberculosis 1.1
 
Over the centuries, the world has recorded a tremendous impact in the discovery and 
the evolution of tuberculosis (TB). TB has been present in humans since ancient 
times throughout known history and human prehistory. The scientific discovery of 
TB has been documented in China, India and Egypt at around 2, 300, 3, 300 and 5, 
000 years ago, respectively (reviewed by Zink et al., 2003). Evidence for the 
presence of M. tuberculosis complex has been recorded in ancient skeletal and 
mummified materials as early as 2125 BC (Donoghue et al., 2009) . The DNA 
analysis of tissue samples from Egyptian mummies has shown that the original M. 
tuberculosis complex was similar to the present M. tuberculosis strains (Baron et al., 
1996).    
 
M. tuberculosis was first identified in 1882 when Robert Koch (1843-1910) 
succeeded in visualizing and described that the tubercle bacillus as aetiologic agent 
of TB (reviewed by Cambau and Drancourt, 2014). Later in 1896, the 
Mycobacterium genus was included into the Mycobacteriaceae family by Lehman 
and Neuman (Ostroff, 2008).  
 
Since the past few decades, TB has emerged as a major global threat and 
efforts have been focused to reduce TB disease burden.  The Stop TB Strategy 
mooted by WHO have leaded a serious effort by global scientists in the field to 
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reduce the prevalence of TB and the mortality associated with the disease. One of the 
main components of the Stop TB Strategy in the context of the Millenium 
Development Goals (MDGs) towards reduction of TB burden has been directed to 
the continuous research for the identification of new anti-TB drugs and biomarkers. 
The development of new vaccines and diagnostic tools are part of the main efforts to 
eradicate the overwhelming threat of TB. 
   
 Epidemiology of tuberculosis 1.2
 
TB remains a major global scourge. It infects millions of people each year and causes 
significant public health challenges especially in developing countries. It is estimated 
that one-third of the world’s population is infected with M. tuberculosis. However, 
the vast majority of infected individuals are protected by the host’s immune system 
and not showing any symptoms of active TB disease. As a consequence, these 
individuals are healthy but remain latently infected with M. tuberculosis. About 5-10 
% of newly or latently infected individuals develop TB disease which results in 
unacceptable number of annual death tolls (WHO, 2011).  
 
The extent of TB epidemics can be classified as high prevalence and low 
prevalence areas in which the burden and rates of TB are variably distributed 
throughout the world. The high prevalence areas are countries that suffer TB 
epidemics with an incidence rate of more than 100 per 100, 000 population. These 
are mostly countries in Africa with the highest rates per capita while developing 
countries in Asia show the highest number of TB cases (Figure 1.1).  
 
 3 
 
 
 
 
 
 
 
Figure 1.1: Estimated TB incidence rates by different regions and countries, 2010. 
(WHO, 2011)   
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In 2014, WHO estimated that 14 million people have active TB. There were 
about 1.5 million deaths due to TB including 0.4 million co-infected with the human 
immunodeficiency virus (HIV) (WHO, 2011). Numerous factors have been 
associated with the increase in global TB incidence which includes the emergence of 
multi-drug resistant (MDR) and extensively drug resistant (XDR) strains of M. 
tuberculosis, immigration from high TB prevalence areas and increased number of 
immune compromised patients (reviewed by Millet et al., 2010). HIV-induced 
immunosuppression greatly enhances the reactivation of TB disease due to weakened 
immune responses (Selwyn et al., 1989; WHO, 2011) . However since 2006, a steep 
decline in TB incidence has been recorded as a result of global efforts in TB control 
by the comprehensive implementation of Directly Observed Therapy Strategy 
(DOTS). Several remarkable successes in TB control have been recorded after the 
implementation of DOTS. The most significant achievement of DOTS between 1995 
and 2010, is represented by the fact that almost 55 million active TB patients were 
successfully treated under continuous surveillance by the national control 
programmes using the WHO-promoted plan (reviewed by Hill and Whalen, 2014).  
 
 The organism: Mycobacterium tuberculosis 1.3
 
Mycobacteria belong to the family of Mycobacteriaceae and the order 
Actinomycetes. M. tuberculosis is a non-motile, straight or slightly curved rod-
shaped and non-spore forming bacterium. The mycobacteria size is approximately 1-
4 µm in length and between 0.2-0.6 µm in width, making them smaller than most 
bacterial pathogens. These organisms usually contain granules and vacuoles but they 
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do not form capsules, flagella or spores. M. tuberculosis is an obligate aerobe and 
intracellular bacterium, and has a slow generation time between 15 to 20 hours.  
 
Several species of mycobacteria, with almost identical growth characteristics 
and biochemical reactivity are classified into the M. tuberculosis complex (MTBC). 
The MTBC includes M. bovis, M. africanum, M. canetti and M. microti which also 
caused TB in mammals. M. bovis is the causative agent of bovine TB and infects 
mammalian species including humans (Ayele et al., 2004). Among the large 
spectrum of mycobacterial species, M. tuberculosis is the main aetiologic agent of 
TB in humans.   
 
The cell wall of M. tuberculosis is unique and contains lipid-rich component 
compared to other prokaryotes. The major M. tuberculosis cell wall component is 
lipid which constitutes more than 60% of the total mass and gives unique 
characteristic to the bacterium. In general, the mycobacterial cell wall consists of a 
highly structured lipid component known as mycolyl-arabinogalactan-peptidoglycan 
(mAGP) complex. The mAGP complex, mycolic acids and extractable lipids formed 
the mycobacterial outer membrane. The mycolic acid provides a hydrophobic layer 
for intercalating additional complex lipids, which make the mycobacteria highly 
resistant for the penetration of antibiotics (Minnikin et al., 2002) (Figure 1.2)  
 
Other type of lipids and glycolipids found in mycobacteria cell-wall include 
phosphatidyl-myo-inositol mannosides (PIMs), lipomannan (LM) and 
lipoarabinomannan (LAM) (Brennan & Nikaido, 1995; Morita et al., 2004).  These 
complex glycoconjugates are the main virulent components in modulating the host- 
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Figure 1.2: Structure of mycobacteria cell wall (Brown et al., 2015). 
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response during infection. PIMs, LM and LAM have several immunomodulatory 
features by mediating the interaction with different receptors of the immune system 
(Schlesinger et al., 2008). LAM and related glycoconjugates are unique across 
species as the biochemical analysis of the mycobacterial cell wall show different 
variants of lipids (Mishra et al., 2011). For example, in M. tuberculosis and other 
pathogenic mycobacteria, the end-product of LAM biosynthesis is different from that 
of non-pathogenic M. smegmatis (Figure 1.3). This suggests a different degree of 
virulence among mycobacterial species which is associated with the biosynthesis of 
cell wall lipids (Mishra et al., 2011).  
 
 Pathophysiology of tuberculosis 1.4
 
TB is an air borne disease and is acquired when a person inhales droplet containing 
M. tuberculosis. The droplet is a particle containing the tubercle bacilli, and this very 
fine particle pass through the nasal passages to reach the alveoli of the lungs 
(Kaufmann, 2002).  
 
The pathogenesis of M. tuberculosis infection can be characterized into three 
different but interrelated interactions between the pathogen and host (Figure 1.4). 
The first stage is the entrance of M. tuberculosis into the lungs where the inhaled 
bacteria penetrate into the terminal alveoli. After inhalation, particles containing one 
to three bacilli reaches the lungs where they are phagocytosed by immune cells: 
alveolar macrophages (AM) and dendritic cells (DC) (Cooper, 2009). Usually most 
of the internalized bacilli are destroyed at this stage; however, the bactericidal 
capacity of the AM is not clear (van Crevel et al., 2003).  
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Figure 1.3: The similarities and differences of the cell wall structure of M. 
tuberculosis and M. smegmatis (Mishra et al., 2011). 
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Figure 1.4: A schematic overview of host immune response against M. 
tuberculosis infection (Yuk and Jo, 2014).  
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The bacilli that evade the initial elimination will multiply in a hostile 
macrophage environment and M. tuberculosis has evolved various mechanisms to 
ensure their survival in AM. The survival mechanisms used by M. tuberculosis 
include the inhibition of the reactive oxygen and nitrogen intermediates production 
(ROIs and RNIs, respectively) inhibition of the phagosomal maturation by reducing 
its acidification and induction of anti-inflammatory responses (Flynn, 2006; Cooper, 
2009; Welin et al., 2011).  
 
If the M. tuberculosis growth is arrested at early stage of infection, then the 
disease is maintained in latent condition without TB symptoms in 90-95% of infected 
individuals. Otherwise, in 5-10 % M. tuberculosis infected individuals,  the bacilli 
replicate into macrophages and disseminated to other tissues and organs, where 
active TB develops with typical clinical symptoms including weight loss, chest pain, 
frequent coughing and fatigue (Ahmad, 2011).  
 
The second stage of infection is the establishment of cell mediated immune 
response and the formation of granulomas. In most cases, tubercle bacilli that escape 
the bactericidal effect of AM will establish the infection and result in destruction of 
AMs. This will in turn leads to a chemotactic response that brings monocyte-derived 
DCs and other inflammatory cells such as neutrophils to the area of infected lungs 
(Schreiber et al., 2010). At this stage M. tuberculosis grows logarithmically with 
limited tissue damage. Activated antigen-specific T lymphocytes that migrate to the 
site of infection will proliferate forming an early lesion or tubercle, where 
macrophages become activated to kill intracellular M. tuberculosis (Ulrichs and 
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Kaufmann, 2006). This phase of infection with continuing T cell activation leads to 
formation of granulomas where the growth of mycobacteria is put in checks which 
mark the persistent stage of infection or a phenomenon called as latency (Ahmad, 
2011)(Figure 1.5). 
 
The final stage is the reactivation of latent infection into active TB disease. 
Reactivation of latent M. tuberculosis infection can occur months or years afterwards 
when the immune system fails to contain the bacillary growth in conditions of 
impaired immune response. This stage requires dormant M. tuberculosis cells to exit 
the phase of latency. There are several reasons that can trigger a reactivation event to 
occur, and this typically involves the failure to maintain immune competency due to 
a weakening immune system. Under these conditions, the intact granuloma is 
structurally disrupted resulting in lung cavitation that leads to appearance of 
pulmonary disease. Impaired immune function as a result of HIV infection is the 
most important risk factor for progression to active disease, where a host becomes 
immuno compromised due to depletion of CD4
+
 T cells and dysfunctional CD4
+
 and 
CD8
+ 
T cells which play important role in protection against TB (Wells et al., 2007).  
 
In latent TB infection, M. tuberculosis continues to survive within the intact 
granulomas but there are no signs or symptoms of TB. Latently infected individuals 
cannot spread the bacteria to the environment or other people, but are at risk of 
developing active TB disease. Active TB patients exhibit signs and symptoms of the 
disease and have a high probability to spread the bacteria to others (Ahmad, 2011).  
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Figure 1.5:  Pathogenesis and transmission profile of M. tuberculosis (Hossain and 
Norazmi, 2013).  
Functional innate immunity is capable to protect the host from M. tuberculosis 
infection in the majority of individuals, while impaired innate immune response 
leads to M. tuberculosis infection. Activated adaptive immunity then controls the 
intracellular growth of M. tuberculosis. The formation of granulomas which contain 
persistent M. tuberculosis surrounded by immune cells marked the state of latent TB 
infection. Defective adaptive immunity causes active TB and promotes reactivation 
of the latent TB. 
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TB disease can be categorized into two main types, according to site of M. 
tuberculosis infection in the body and where the infection manifests itself. The two 
types are described as pulmonary and extrapulmonary TB. Pulmonary TB is the 
contagious form of the disease and accounts for 80-85 % of cases which represents 
the highest prevalence of death due to TB. Extrapulmonary TB is a result of 
disseminated M. tuberculosis infection to various adjacent organs from the lungs. 
This form of TB can spread to many different parts of the body through the 
bloodstream including meninges, peritoneum, bones, lymph nodes, pleura, spinal and 
spine. Extrapulmonary TB is commonly detected in TB patients co-infected with 
HIV (Gray and Cohn, 2013). 
 
 Diagnosis and therapy of tuberculosis 1.5
 
The Global Plan to Stop TB was launched in 2006 by the STOP TB Partnership, 
which set a global blueprint strategy for substantially minimizing TB burden by 
2015. The research and development (R&D) component of the Global Plan to Stop 
TB envisaged that fundamental basic research will pave the way for discovery of 
new diagnostics, drugs and vaccines (WHO, 2010) . In addition, TB infection control 
was established by a combination of measures aimed at reducing the risk of TB 
transmission within population (Mwaba et al., 2011). The DOTS programme was 
successfully expanded as the principal TB control strategy, focusing primarily on 
detection and effective treatment of TB cases (Lawn and Zumla, 2011).  
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1.5.1 Diagnosis 
 
The standard technique used in TB diagnostic laboratory is microscopic examination 
of acid fast bacillus, followed by culture on solid or liquid media for confirmation. 
Conventional smear microscopy based on Ziehl-Neelsen staining of sputum 
specimens with light microscope has been applied for over 100 years in low-resource 
settings. Microscopy technique helps in the initial diagnosis of TB especially in cases 
of active infection detection. However, the light microscopy technique is relatively 
insensitive for the diagnosis of TB as it can only detect the AFB concentration of at 
least 10
5
 AFB per mL of specimen and only detects about 60-70 % of TB cases. 
Alternatively, fluorescence microscopy technique is 10% more sensitive since the 
fluorescent bacilli of M. tuberculosis can be seen at lower magnification (Steingart et 
al., 2006).  
 
The isolation of M. tuberculosis on a culture medium remains as a gold 
standard test for TB diagnosis. In this regard, active TB infection is definitive when 
the organism is directly isolated from human specimens using microbiological 
culture (WHO, 2010). The most commonly used solid medium is the egg-based 
Lowenstein Jensen (LJ) medium and a broth based growth system, the BACTEC 
460. Liquid medium has been reported to be more efficient and possess 20 % 
increased sensitivity for the growth and reduced the delay for detection of M. 
tuberculosis.   A drawback of the solid LJ culture method is that the result of M. 
tuberculosis culture positivity can be obtained only after 2 to 4 weeks or even longer, 
and in 10-20 % of cases the bacillus is not successfully cultured. In contrast, the 
average time for M. tuberculosis detection with BACTEC 460 is 15 days and 
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BACTEC MGIT960 system require 13 days of culture (Huang et al., 2001; Cruciani 
et al., 2004). However, the contamination rate of liquid medium seems to be higher 
in comparison with the solid media (Somoskovi et al., 2000). Safety issues 
concerning the radioactivity of BACTEC and the cost of waste disposal management 
prevents its widespread application.  
  
The most important molecular test used for laboratory diagnosis of 
pulmonary TB is the nucleic acid amplification test (NAAT). NAAT is performed 
following microscopy to distinguish M. tuberculosis from other smear-positive 
mycobacteria. In general, the most common NAAT method used is polymerase chain 
reaction (PCR). The test is usually performed on sputum or broncho alveolar lavage 
(BAL) specimens, to detect small amounts of genetic material (DNA or RNA target 
gene sequence) from M. tuberculosis by repetitive amplification of the target 
sequences.  
 
The main immune mechanism against M. tuberculosis infection is based on 
the mycobacteria-specific responses of T-cells that can be determined by cellular 
assays such as tuberculin skin test (TST) and IFN-γ release assay (IGRA). TST is an 
in vivo test based on the intradermal administration of a sterile supernatant derived 
from M. tuberculosis-cultured filtrate protein known as purified protein derivatives 
(PPD). The exposure to PPD results in a delayed-type hypersensitivity reaction, and 
the diameter of local skin induration is then measured 48-72 h after antigen injection 
(Sokal, 1975). The low specificity in TST is due to exposure to BCG vaccination and 
previous exposure to environmental mycobacteria resulting in false-positive results. 
The drawbacks of TST procedure has been highlighted, among others are due to 
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inconsistent inoculation of tuberculin and problem associated with the reading of the 
test as it is operator-dependent and requires the patient to return to the health care 
centre for result interpretation (Lange and Mori, 2010). Thus, IGRA has been 
developed trying overcome the disadvantages of the TST. 
 
IGRA is based on the detection of two specific gene products from M. 
tuberculosis: culture filtrate protein 10 (CFP-10) and 6-kDa early secreted antigenic 
target (ESAT-6). These genes codify immmunodominant antigens that are absent in 
BCG and most environmental mycobacteria, decreasing the possibility to elicit false 
positive responses (Harboe et al., 1996). Two types of commercially available IGRA 
have been developed based on the measurement of IFN-γ production using ELISA, 
known as QuantiFERON
® 
TB Gold and the latter version of QuantiFERON
® 
TB- 
Gold In Tube (QFT-GIT) (Cellestis Ltd, Carnegie, Australia). Another 
commercialized IGRA, T-SPOT TB is based on the counts of the cells producing 
IFN-γ visualized as spots with the enzyme-linked immunospot (ELISPOT) method 
(Oxford Immunotec Ltd, Abingdon, UK) (Mori, 2009).
 
 
 
IGRA specificity is higher and superior compared to TST. Although IGRA is 
unable to distinguish between active TB and LTBI, IGRA results are not confounded 
by BCG vaccination as well as exposure to NTM. Therefore, IGRA has an important 
advantage over TST for the determination of human immune response to M. 
tuberculosis, especially in the population with high exposure of environmental 
mycobacteria.  
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1.5.2 Therapy 
 
TB can be treated by chemotherapy and the aim of this treatment is to render the 
patient non-infectious by elimination of all mycobacteria, thus preventing spread of 
the disease. In addition, the objective of an effective treatment is to prevent 
generation and transmission of resistant mycobacteria. Implementation of DOTS in 
TB treatment results in a major improvement in global TB control. In Malaysia, 
treatment of TB is based on the Clinical Practice Guidelines for the Control and 
Management of TB, endorsed by the Ministry of Health, Malaysia. TB treatment 
regime involve two phases; intensive and continuation phase, respectively. The 
outcome of intensive phase treatment could be observed by rapid sputum conversion 
and improving clinical condition. While during the continuation phase the treatment 
will eliminate the remaining bacilli and minimize the chance for relapse.  
 
There are a number of anti-TB drugs available including p-aminosalicylic 
acid (PAS), Isoniazid (INH), Cycloserine, Kanamycin, Pyrazinamide (PZA), 
Rifampicin (RIF) and Ethambutol (ETH). The usual standard drug regimen of short 
course chemotherapy consists of 2 months of INH, RIF, PZA and ETH, followed by 
4 months of INH and RIF (CDC, 2014). The patients’ compliance to the prescribed 
treatment regimen is a pre-requisite for successful treatment. TB therapy is relatively 
cheap but the long treatment regimens often leads to non-compliance and hence 
results in development of MDR-TB strains (Espinal, 2003). Furthermore, 
interruption of the antibiotic course may have serious consequences where TB cannot 
be cured or M. tuberculosis can spread to others (Goble et al., 1993). Thus in 
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addition to developing more effective drugs that require much shorter treatment 
regimens, other effective strategies such as vaccines needs to be developed.  
 
 The host immune response to Mycobacterium tuberculosis 1.6
 
The immune system involves recognition and discrimination of foreign agents as not 
part of the body and the development of an immune response against them. Defence 
against foreign invaders or antigens, such as microbes are mediated by initial 
interaction with innate immune cells and the later responses of adaptive immunity.  
 
Innate immunity provides the first line of defence against intracellular 
bacterial infection, such as M. tuberculosis. The later response for mycobactericidal 
processes mainly depends on the synergistic interaction between infected 
macrophages and T lymphocytes. The pivotal roles of innate immunity during the 
early phase of infection substantially influence adaptive immunity. The professional 
antigen presenting cells such as macrophages and DCs are the main host cells 
involved in the innate immune response to mycobacteria, and play a critical role in 
the initiation of adaptive immunity through various mechanisms and signaling events 
(van Crevel et al., 2003). M. tuberculosis infection induced both humoral and cell-
mediated immune responses through a complex interaction between the pathogen 
and infected host.  In this context, it is clear that innate and adaptive immunity are 
closely connected.  
 
 
 
 
 19 
 
1.6.1 Innate immune response to Mycobacterium tuberculosis 
 
Early after inhalation of M. tuberculosis, alveolar macrophages are the primary cell 
type involved in the initial uptake and phagocytosis of the bacilli. After this first 
encounter, monocyte-derived macrophages and DCs modulated the phagocytic 
process. The infection process is initiated after recognition of pathogen-associated 
molecular patterns (PAMP) of M. tuberculosis by specific pathogen recognition 
receptors (PRR) expressed on phagocytic cells. This pathogen-host interaction is 
central in the initiation and coordination of the host innate immune response that 
determines the fate of ingested M. tuberculosis (Akira et al., 2006).  On the host side, 
phagocytic antigen presenting cells are equipped with specific PRRs capable of 
recognizing M. tuberculosis.  
 
Prior to phagocytosis,  M. tuberculosis or mycobacterial products are 
recognized by host PRRs, such as Toll-like receptors (TLR), complement receptors 
(CR), nucleotide binding oligomerization domain (NOD) like receptors (NLR), and 
C-type lectins family. The C-type lectins include the mannose receptor, the dendritic 
cell-specific intercellular adhesion molecule grabbing nonintegrin (DC-SIGN) and 
Dectin-1 (El-Etr and Cirillo, 2001; Jo, 2008; Harding and Boom, 2010). TLRs are the 
best studied innate immune receptors involved in recognition of PAMPs of 
pathogens. In mycobacterial infection, interaction of TLRs ligands with the PAMPs 
expressed by mycobacteria leads to macrophage activation and triggers downstream 
intracellular signaling cascades (Figure 1.6). 
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Figure 1.6: Recognition of M. tuberculosis or its components by the host’s 
immune receptor during phagocytosis (Hossain and Norazmi, 2013). 
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Activated macrophages are involved in the regulation of several aspects of 
the immune response such as the production of proinflammatory cytokines and 
chemokines, antimicrobial metabolites to kill infected cells, and antigen presentation 
that bridged the adaptive immunity (Figure 1.7) (Kleinnijenhuis et al., 2011). 
Important pro-inflammatory innate cytokines produced by activated macrophages 
includes TNF-α, IFN-γ, IL-1β, IL-18 and IL-12 (Sato et al., 2002; Sharma et al., 
2007).  TNF-α is secreted by infected macrophages to recruit activated CD4 and CD8 
T cells to the site of infection (Mohan et al., 2001). In turn, IFN-γ production is 
induced and further activates the macrophages (Flynn, 2006). Mycobactericidal 
effects are mainly triggered by activated macrophages and by cytotoxic function of T 
cells. The killing effect is also modulated by TNF-α inducing apoptosis of infected 
macrophages. Thus, the balance of pro- and anti-inflammatory cytokines fine tune 
the cells communication which in turn regulate the immune response (Romero-
Adrian et al., 2015).  
 
Activated macrophages are well equipped with several proteolytic enzymes in 
the phagolysosome to destroy the microbes (Connelly et al., 2003). In addition, 
activated macrophages convert molecular oxygen into reactive oxygen species 
(ROS), which act as highly reactive oxidizing agents that promote bactericidal 
effects on the infected cells (Alderton et al., 2001) . Other important metabolites 
produced by activated macrophages are reactive nitrogen intermediates (RNI), 
mainly nitric oxide (NO). Production of NO is catalyzed by the expression of an 
enzyme called inducible nitric oxide synthase (iNOS), induced in various cells 
including macrophages, neutrophils and epithelial cells (Bosca et al., 2005).  
 
 22 
 
 
 
 
 
 
Figure 1.7: Effector functions of macrophages (Abbas et al., 2007). 
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NO is mainly produced in response to the microbial products that activate 
TLRs, especially in combination with cytokines and chemokines (Nathan and Shiloh, 
2000). It has been well described that stimulation of iNOS is positively regulated by 
Th1 cytokines (IFN-γ, TNF-α), and negatively regulated by Th2 cytokines (IL-10, 
IL-4) (Figure 1.8) (Sharma et al., 2004; Roy et al., 2014). iNOS catalyzes the 
conversion of arginine to citrulline, which results in the production of diffusible NO. 
Within phagolysosomes, the increase in RNIs is generated by the reaction of NO 
with O2
-
 which is capable to kill the microbes. The killing mechanisms are 
modulated by NO and RNI through the modification of bacterial DNA, proteins and 
lipids in both the pathogen and infected host cells (Chan et al., 1995).   
 
During infection with M. tuberculosis, iNOS knock-out and immunodeficient 
mice are at significantly higher risk of dissemination and had lower survival rate as 
compared to control mice (MacMicking et al., 1997). Contrasting data have been 
reported regarding the role of NO and iNOS in the killing and inhibition of M. 
tuberculosis in mice model versus humans. Evidences indicated that early inhibition 
of mycobacterial growth by human alveolar macrophages is independent of NO 
production (Bingisser and Holt, 2001; Davis et al., 2007). Nevertheless, several 
reports described a role for NO in human host responses against M. tuberculosis. 
Studies have demonstrated that alveolar macrophages modulates the 
mycobactericidal effects dependent on iNOS expression (Nozaki et al., 1997).  
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Figure 1.8: Mechanism of regulation and anti-mycobacterial function of NO. 
(Yang et al., 2009). 
  
